zealand_logo_RGB_01.png
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
20 juin 2024 11h37 HE | Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
zealand_logo_RGB_01.png
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
31 mai 2024 10h03 HE | Zealand Pharma
Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency ...
zealand_logo_RGB_01.png
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
23 mai 2024 14h45 HE | Zealand Pharma
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
zealand_logo_RGB_01.png
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
08 janv. 2024 15h45 HE | Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...
zealand_logo_RGB_01.png
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
02 janv. 2024 02h00 HE | Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
zealand_logo_RGB_01.png
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
04 déc. 2023 02h30 HE | Zealand Pharma
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and...
zealand_logo_RGB_01.png
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
30 nov. 2023 02h00 HE | Zealand Pharma
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no....
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
09 nov. 2023 01h00 HE | Zealand Pharma
Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for...
zealand_logo_RGB_01.png
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
07 nov. 2023 04h00 HE | Zealand Pharma
Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
zealand_logo_RGB_01.png
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
03 nov. 2023 12h00 HE | Zealand Pharma
Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand...